Depressed cell-mediated immunity in patients with primary intracranial tumors. Characterization of a humoral immunosuppressive factor. - Wikidata - wikimedia - TriplyDB

Depressed cell-mediated immunity in patients with primary intracranial tumors. Characterization of a humoral immunosuppressive factor.

Depressed cell-mediated immunity in patients with primary intracranial tumors. Characterization of a humoral immunosuppressive factor.

http://www.wikidata.org/entity/Q30442773

about

Complementary DNA for human glioblastoma-derived T cell suppressor factor, a novel member of the transforming growth factor-beta gene family Immunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS Sites Immunotherapy for brain cancer: recent progress and future promise The future role of personalized medicine in the treatment of glioblastoma multiforme U87MG glioma cells overexpressing IL-17 acclerate early-stage growth in vivo and cause a higher level of CD31 mRNA expression in tumor tissues Cell-mediated immunity and its role in resistance to infection.Characterizaiton of two populations of human lymphocytes bearing easily detectable surface immunoglobulin.Antigens in human glioblastomas and meningiomas: Search for tumour and onco-foetal antigens. Estimation of S-100 and GFA protein.Combining cytotoxic and immune-mediated gene therapy to treat brain tumors History and current state of immunotherapy in glioma and brain metastasis.T cell suppressor factor from human glioblastoma cells is a 12.5-kd protein closely related to transforming growth factor-beta T-cell TGF-β signaling abrogation restricts medulloblastoma progression.Inability of mitogen-activated lymphocytes obtained from patients with malignant primary intracranial tumors to express high affinity interleukin 2 receptors.Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study Influenza vaccine immunogenicity in patients with primary central nervous system malignancy.Cell-mediated immunotherapy: a new approach to the treatment of malignant glioma.Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors Inhibitors of Glioma Growth that Reveal the Tumour to the Immune System.Immunotherapeutic strategies for malignant glioma.Recent progress in immunotherapy for malignant glioma: treatment strategies and results from clinical trials.Immunobiologic aspects of the brain and human gliomas. A review The evolution of the EGFRvIII (rindopepimut) immunotherapy for glioblastoma multiforme patients A preliminary study utilizing viable HLA mismatched cultured glioma cells as adjuvant therapy for patients with malignant gliomas.Immunotherapy of malignant brain tumors.Therapeutic administration of IL-15 superagonist complex ALT-803 leads to long-term survival and durable antitumor immune response in a murine glioblastoma model.Glioma-specific antigens for immune tumor therapy.Combating immunosuppression in glioma Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma.Immunotherapeutic approaches for glioma Immunosuppression by a mouse tumor resembles antigenic competition.The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial.Cancer immunoediting in malignant glioma.Current challenges in designing GBM trials for immunotherapy.Novel vaccines for glioblastoma: clinical update and perspective.Opioids: immunomodulators. A proposed role in cancer and aging.Current knowledge and concepts of the relationship of malignancy, autoimmunity, and immunologic disease.Impaired immunoresponsiveness in tumor patients.Inhibiting TGF-beta signaling restores immune surveillance in the SMA-560 glioma model.Invited review. Nervous system antigens.

P2860

Q24298014-C0529A20-B62F-4B90-B7E1-C31ED5FA26E4 Q26798402-B0A50EAF-7648-4529-9E6E-F4C31222D488 Q27015881-BDD849F8-31EA-4670-A825-F73A606A3431 Q28391635-8DA966AA-456A-49D6-A3FF-A6502C6CE592 Q28674494-314AA9BB-3418-4548-9AA7-4747E1D50C50 Q30447984-6DC9B86A-0CA9-4304-B085-4F63E02FCE0E Q30449432-BDD056C1-D1FE-4F81-B5B3-12505FCD61E2 Q30486908-5040D354-8448-44A1-9C94-F9A2CEE3F6EC Q31013320-D434908A-A24B-4239-A9D2-59F72D107DFF Q33656811-852FE9B2-D04E-4A2F-B4BA-7FECE385DFAE Q33929154-613A725D-0B81-4524-A5FF-1338F0C7A11D Q34082913-04A55406-D1D4-4AF7-86CB-3FA22CC8254C Q34255250-CD290CB0-2AA3-4427-B566-0DFB5849046A Q34480536-496E5CB8-3EAF-4B92-A75D-EBE5AACE9DD5 Q34511678-91136E60-5055-46D2-B93B-7794ABBCC67A Q35113661-F53E8C6E-FE7B-4653-9226-1F89311A6036 Q35162055-EA9DB464-E26F-432A-91DE-7E9616979BCD Q35440540-0EAFB9ED-F706-4FDD-96B1-E94722A6BE9E Q35778576-C45C949A-1616-43F8-ADE8-E99DF80C2AEE Q35778581-C28C1070-ACD2-4A35-87BB-FADE8D6E53E3 Q35862927-8C87CF19-56F0-4433-BD66-B7CE3196363B Q35886554-DAF72A6D-2710-45F9-A34A-B360C7CB9E9A Q35992089-4D6579D8-460B-43B3-9E6A-F8CCC05A7F8F Q36162929-DA62B582-3215-4794-9E05-CF640B8C936D Q36416387-F6A861DD-A037-4C14-BE02-8AC084C9C2FF Q36690281-75076D6B-BF33-4571-BE1E-ACC98D0A9750 Q37179415-38253B4E-B13F-4F0F-BFA7-C6A0F1F5B14E Q37186248-1022F136-92F9-4D82-8531-0929BF664716 Q37267793-5BF83E34-FCE5-49E7-B908-D14056EE6C73 Q37333842-B6232369-9720-4564-A4AC-F9E80B3C90BD Q37475929-059682D5-E9B7-4A06-ABFB-2A6AC003BDC3 Q37492175-FB746EF4-7CDD-4187-92BE-107A808F4B7C Q37986999-46911EB8-2238-408F-83C8-DB795DC9228F Q38313826-CA7BD4AA-4FE0-4385-990C-787F726BACCA Q39043417-59BB6A54-B27A-4BE2-B5B9-4DF2B9DB4E70 Q39644252-588A1BCA-2F1F-4D9B-8BBA-2AC8556C971E Q39870306-26D91ABB-022A-4603-813E-126F593E3E78 Q39939888-2592045A-EC93-4658-B118-2BC82393587C Q40128542-D803BFEB-89DF-4B43-A992-F17F4D01113A Q40147866-89A5929C-DF79-449C-B1EE-EB0CB217EA78

P2860

Depressed cell-mediated immunity in patients with primary intracranial tumors. Characterization of a humoral immunosuppressive factor.

http://www.wikidata.org/entity/Q30442773

description

1972 nî lūn-bûn

@nan

1972 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

1972 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

1972年の論文

@ja

1972年論文

@yue

1972年論文

@zh-hant

1972年論文

@zh-hk

1972年論文

@zh-mo

1972年論文

@zh-tw

1972年论文

@wuu

name

Depressed cell-mediated immuni ...... oral immunosuppressive factor.

@ast

Depressed cell-mediated immuni ...... oral immunosuppressive factor.

@en

type

label

Depressed cell-mediated immuni ...... oral immunosuppressive factor.

@ast

Depressed cell-mediated immuni ...... oral immunosuppressive factor.

@en

prefLabel

Depressed cell-mediated immuni ...... oral immunosuppressive factor.

@ast

Depressed cell-mediated immuni ...... oral immunosuppressive factor.

@en

P1433

Q30442773-5DC20ED8-FC7C-4B91-A34F-52C572324175

P1476

Q30442773-C6E82F20-19A9-4502-A02F-6CEABB9015E4

P2093

Q30442773-1A66378B-CE9C-4AEF-9580-BC7B6F885319

Q30442773-A83673D1-29C6-4052-B532-B38D79F93480

Q30442773-EFEB724F-D130-42CB-8F55-D35BE8FE8AD1

Q30442773-F4E67FD6-5182-4465-A1D3-1D56FCBD06A7

P2860

Q30442773-1C2FEADC-F84C-4BBA-931E-CC831028D1EE

Q30442773-2208162D-37B5-4615-A9FA-83571902C2C0

Q30442773-29CE641B-D475-4AC8-8FB8-3139369EC9DA

Q30442773-2B89760A-2709-4DEB-9815-D5CD5D8F1032

Q30442773-31E5B711-4E48-4CE7-83D4-F1123EEF0621

Q30442773-A6E474BA-99A0-446C-90D6-4D5094952B81

Q30442773-B33FE47C-CBF1-4909-8F56-E0EAC6B6A2AD

Q30442773-C64ED2E2-1EC8-4C19-AE76-D8660393E804

Q30442773-C936A9C2-E306-43F3-84A7-1CF30CCAF71D

Q30442773-EA58E8A3-33BD-464F-A177-DEC36730BEC0

P304

Q30442773-2481EEB2-FCE8-45CA-B9D9-E40380F8DABE

P31

Q30442773-005261A5-615D-44D9-B47C-5C0097477694

P356

Q30442773-030CE282-B074-44F1-A94D-042DCBF05C60

P407

Q30442773-00621216-B8B7-4E32-A9E4-39397FC92502

P433

Q30442773-F22AE0C9-0B9B-404B-8BD9-3019EFB2FD72

P478

Q30442773-0A95C648-93BC-4E49-910A-644108B196DA

P577

Q30442773-57E699E8-A92B-40D9-909E-FAFB9A055033

P5875

Q30442773-1CFB10DB-64D4-49F1-BE29-C4993DF36A70

P698

Q30442773-BC38C669-EDCA-4900-A1B7-23EDBD551A6E

P932

Q30442773-31751DBC-7F04-4FD1-BC37-992CFB3A8E4D

P356

P1433

Journal of Experimental Medicine

P1476

Depressed cell-mediated immuni ...... oral immunosuppressive factor.

@en

P2093

Brooks WH

http://www.w3.org/2001/XMLSchema#string

Horwitz DA

http://www.w3.org/2001/XMLSchema#string

Netsky MG

http://www.w3.org/2001/XMLSchema#string

Normansell DE

http://www.w3.org/2001/XMLSchema#string

P2860

The development of macrophages from large mononuclear cells in the blood of patients with inflammatory disease

The termination of immunological unresponsiveness to bovine serum albumin in rabbits. I. Quantitative and qualitative response to cross-reacting albumins.

Antibody-mediated suppression of the immune response in vitro. I. Evidence for a central effect

Suggestive evidence that the "blocking antibodies" of tumor-bearing individuals may be antigen--antibody complexes.

Immunological enhancement as studied by cell culture techniques.

Transformation of human lymphocytes: inhibition by homologous alpha globulin.

Effect of plasma from patients with carcinoma on in vitro lymphocyte transformation.

Dynamics of immunologic enhancement.

In vitro demonstration of cell-mediated immunity to human brain tumors.

Brain-associated theta antigen: reactivity of rabbit anti-mouse brain with mouse lymphoid cells.

P304

1631-1647

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1084/JEM.136.6.1631

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

136

http://www.w3.org/2001/XMLSchema#string

P577

1972-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

18821043

http://www.w3.org/2001/XMLSchema#string

P698

4345108

http://www.w3.org/2001/XMLSchema#string

P932

2139329

http://www.w3.org/2001/XMLSchema#string